このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

乳房異常患者に対する乳房生検に関する分子乳房画像診断ガイダンス

2026年9月30日 更新者:Mayo Clinic

分子乳房イメージングを評価するためのパイロット臨床研究 - 乳房異常のサンプリングに関するガイダンス

This clinical trial tests how well molecular breast imaging (MBI) works to guide the collection of a breast biopsy in patients with a breast abnormality. Currently, a biopsy is often guided by either ultrasound or mammography in order to ensure that a sample of the correct part of the breast is taken. Sometimes a lesion or part of the lesion cannot be seen on ultrasound or mammography, and, therefore, a biopsy guided with ultrasound or mammography may not be always be accurate. Studies have shown that high resolution MBI may have potential to improve the detection of some breast tumors. This trial uses a new high-resolution MBI system that may help perform a biopsy using MBI.

調査の概要

詳細な説明

PRIMARY OBJECTIVE:

I. To evaluate a methodology for MBI-guided biopsy of suspicious breast lesions.

OUTLINE: Patients are assigned to 1 of 2 study parts.

PART I: Patients receive technetium Tc-99m sestamibi intravenously (IV) and undergo MBI on study.

PART II: Patients receive technetium Tc-99m sestamibi IV and undergo MBI. Patients whose breast lesions of interest are visualized on MBI then undergo breast biopsy using the Stereo Navigator accessory.

After completion of study intervention, patients may be asked to follow up at 3-6 months.

研究の種類

介入

入学 (推定)

70

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Minnesota
      • Rochester、Minnesota、アメリカ、55905
        • 募集
        • Mayo Clinic in Rochester
        • コンタクト:
        • 主任研究者:
          • Katie N. Hunt, M.D.

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  • PART I: Women aged 18 years or older

  • PART I: If able to become pregnant, negative pregnancy test within 48 hours prior to MBI biopsy procedure

  • PART I: Individuals who have previously (within the last 3 years) undergo an MBI study and were found to have at least one breast imaging finding on MBI that was subsequently shown (through additional imaging, biopsy or follow-up) to be benign in nature

  • PART I: Individuals who have agreed to participate in the study and who have signed the study-specific informed consent

  • PART II: Women aged 18 years or older

  • PART II: If able to become pregnant, negative pregnancy test within 48 hours prior to MBI biopsy procedure

  • PART II: Individuals who have previously (within the last 3 years) undergone an MBI study and were found to have at least one breast imaging finding on MBI that was subsequently shown (through additional imaging, biopsy or follow-up) to be benign or probably benign in nature

  • PART II: Individuals who had recent conventional imaging work-up including either x-ray mammography, ultrasound, MBI, or MRI of the breast and are found to have at least one breast imaging finding for which biopsy is required or recommended, specifically:

    • Individuals who have a breast abnormality(ies) on imaging with mammography, ultrasound, MBI, or MRI (as per American College of Radiology [ACR] Breast Imaging Reporting and Data System [BIRADS] 3, or higher) and requiring imaging follow-up or biopsy confirmation
  • PART II: Individuals who have agreed to participate in the study and who have signed study-specific informed consent

Exclusion Criteria:

  • PART I: Women who are pregnant
  • PART I: Women who are currently lactating or discontinued breastfeeding < 2 months prior to the study
  • PART I: Age less than 18 years
  • PART I: Women with breast implant(s) in the breast containing the lesion of interest
  • PART I: Inability to provide informed consent
  • PART II: Women who are pregnant
  • PART II: Women who are currently lactating or discontinued breastfeeding < 2 months prior to the study
  • PART II: Age less than 18 years
  • PART II: Women with breast implant(s) in the breast containing the lesion of interest
  • PART II: Women who have recently (within the last 3 months) undergone biopsy of the breast finding
  • PART II: Women who are scheduled for a sentinel node procedure using radioactive Tc-99m within 24 hours of MBI-guided biopsy
  • PART II: Patients with contraindications for core biopsy and other invasive procedures such as blood coagulation disorders, infection, or who are unwilling to discontinue use of anticoagulant medication prior to the procedure
  • PART II: Inability to provide informed consent
  • PART II: Women who have had surgery on the study breast(s) within the past 12 months

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:診断
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Part I (technetium Tc-99m sestamibi, MBI)

Patients receive technetium Tc-99m sestamibi IV and undergo MBI on study.

Undergo MBI

他の名前:
  • MBI
  • 乳房固有のガンマ線イメージング
  • ミラルマスキャン
  • ミラルマテスト
  • 乳房の分子イメージング
  • 核医学 乳房画像
  • セスタミビ乳房画像
  • セスタミビシンチマンモグラフィー

Given IV

他の名前:
  • カーディオライト
  • ミラルマ
  • Tc 99m セスタミビ
  • Tc-99m MIBI
  • Tc99m セスタミビ
  • テクネチウム (99mTc) セスタミビ
  • 99m Tc-メトキシイソブチルイソニトリル
実験的:Part II (technetium Tc-99m sestamibi, MBI, biopsy)

Patients receive technetium Tc-99m sestamibi IV and undergo MBI. Patients whose breast lesions of interest are visualized on MBI then undergo breast biopsy using the Stereo Navigator accessory.

Undergo MBI

他の名前:
  • MBI
  • 乳房固有のガンマ線イメージング
  • ミラルマスキャン
  • ミラルマテスト
  • 乳房の分子イメージング
  • 核医学 乳房画像
  • セスタミビ乳房画像
  • セスタミビシンチマンモグラフィー

Given IV

他の名前:
  • カーディオライト
  • ミラルマ
  • Tc 99m セスタミビ
  • Tc-99m MIBI
  • Tc99m セスタミビ
  • テクネチウム (99mTc) セスタミビ
  • 99m Tc-メトキシイソブチルイソニトリル

Undergo biopsy of breast

他の名前:
  • 乳房生検

Utilization of the Stereo Navigator accessory

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Validation of timeframe
時間枠:Baseline

Time from injection of the technetium Tc-99m sestamibi to identification of the appropriate needle guide hole will be reviewed to determine if and where any improvements in workflow can be made to reduce the overall procedure time for patients.

Baseline
Change in image of lesion
時間枠:Baseline; Up to 6 months

The coordinates of the lesion of interest on the high resolution MBI image will be recorded. The guidance procedure will be considered successful if 1) the pre and post images of the lesion demonstrated one of the following: decreased in size, central or eccentric defect where sampled, or decrease in intensity, or 2) pathology results demonstrate malignancy or a specific benign concordant result.

Baseline; Up to 6 months
Accuracy of depth estimation by difference in attenuation from opposing views
時間枠:Baseline; Up to 6 months

For each patient in whom pathology confirms successful sampling of the lesion seen on high-resolution molecular breast imaging (MBI), the error in depth estimation will be calculated as the average error for each depth estimation method from all core biopsy samples. This will allow comparison of the accuracy of the 3 different depth estimation methods and potentially provide further information on the strengths and weakness of each of the three methods for depth estimation. Uniformity activity along the entire 20 mm core would indicate failure to biopsy the lesion. Any portion of increased uptake will be noted and the center of activity will be determined relative to the mid-point of the core sample. This distance will be recorded as the difference between estimated depth and true depth.

Baseline; Up to 6 months
Accuracy of depth estimation by difference in apparent lesion size
時間枠:Baseline; Up to 6 months

For each patient in whom pathology confirms successful sampling of the lesion seen on MBI, the error in depth estimation will be calculated as the average error for each depth estimation method from all core biopsy samples. This will allow comparison of the accuracy of the 3 different depth estimation methods and potentially provide further information on the strengths and weakness of each of the three methods for depth estimation. Uniformity activity along the entire 20 mm core would indicate failure to biopsy the lesion. Any portion of increased uptake will be noted and the center of activity will be determined relative to the mid-point of the core sample. This distance will be recorded as the difference between estimated depth and true depth.

Baseline; Up to 6 months
Accuracy of depth estimation by triangulation
時間枠:Baseline; Up to 6 months

For each patient in whom pathology confirms successful sampling of the lesion seen on MBI, the error in depth estimation will be calculated as the average error for each depth estimation method from all core biopsy samples. This will allow comparison of the accuracy of the 3 different depth estimation methods and potentially provide further information on the strengths and weakness of each of the three methods for depth estimation. Uniformity activity along the entire 20 mm core would indicate failure to biopsy the lesion. Any portion of increased uptake will be noted and the center of activity will be determined relative to the mid-point of the core sample. This distance will be recorded as the difference between estimated depth and true depth.

Baseline; Up to 6 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Katie N. Hunt, M.D.、Mayo Clinic in Rochester

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年8月26日

一次修了 (推定)

2027年12月31日

研究の完了 (推定)

2027年12月31日

試験登録日

最初に提出

2023年9月13日

QC基準を満たした最初の提出物

2023年9月22日

最初の投稿 (実際)

2023年9月28日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年9月30日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 18-011329
  • 18-011329 (その他の識別子:Mayo Clinic in Rochester)
  • NCI-2023-06047 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する